Antibiotic dispensing practices and antimicrobial stewardship gaps in community pharmacies in Kakamega County, Kenya Authors: Eleanor Turnbull-Jones, Susannah Langtree, Nicholas Mogoi, Anthony Sifuna, Lindsay Gadaffi, Tony Jewell, Eric Ogola, Sarah Nanzigu, Sarah Nanzigu Published: 2026 ABSTRACT BackgroundAntimicrobial resistance (AMR) is a major global health threat, with sub-Saharan Africa bearing a disproportionate burden. Community-level antibiotic dispensing practices remain poorly described in Kenya outside Nairobi.MethodsA total of 504 antibiotic dispensing events were recorded across 22 community pharmacies in Kakamega County, western Kenya, between 3rd and 22nd August 2025. Data collected included dispensing source (over-the-counter [OTC] versus prescription), clinical indication, antibiotics dispensed, course completion, and self-reported repeat antibiotic use within the preceding month. Descriptive analyses were performed, and χ² tests were used to examine associations between dispensing source and selected non-antibiotic dispensing characteristics.ResultsOf the 504 dispensing events, 224 (44.4%) involved OTC dispensing and 278 (55.2%) were prescription-based. The most frequent indications for antibiotic dispensing were upper respiratory tract infections (URTI; n = 156, 31.0%), lower respiratory tract infections (LRTI; n = 95, 18.8%), gastrointestinal infections (n = 65, 12.9%), and skin or soft-tissue infections (n = 55, 10.9%). Across all events, amoxicillin, azithromycin, and metronidazole were the most frequently dispensed antibiotics, with cephalosporins and other broad-spectrum agents used across several indications. Partial antibiotic courses were supplied in 33 (6.5%) dispensing events, most commonly due to financial constraints (15/33, 45.5%). Self-reported antibiotic use within the preceding month occurred in 156 (31.0%) cases.ConclusionsOTC antibiotic access remains widespread in Kakamega County, with substantial use of broad-spectrum agents across multiple clinical indications. Financial barriers contribute to incomplete antibiotic courses. These findings highlight the importance of incorporating community pharmacy dispensing data into county-level antimicrobial stewardship programmes and informing national strategies to optimise antibiotic use. Background Antimicrobial resistance (AMR) remains one of the leading global public health threats, directly responsible for an estimated 1.27 million deaths and associated with 4.95 million deaths globally in 2019, based on the most comprehensive analysis to date. The burden is highest in sub-Saharan Africa [1] The inappropriate use of antibiotics—particularly self-medication, incomplete courses, and dispensing without prescription—accelerates the emergence of resistant pathogens [2]. In Kenya, community pharmacies are a major source of antibiotics for both prescribed and non-prescribed use [3] These pharmacies represent a key interface between health systems and communities, often serving as the first point of care for common infections, particularly where access to formal healthcare is limited. While the Pharmacy and Poisons Act restricts antibiotic sales without prescription, enforcement remains inconsistent, particularly in peri-urban and rural settings. Evidence from Nairobi County indicates that 20–30% of antibiotic transactions occur without valid prescriptions [4], yet data from other counties are scarce. Limited surveillance outside major urban centres hampers local implementation of antimicrobial stewardship (AMS) interventions. To strengthen containment of AMR, Kenya launched the National Action Plan on Antimicrobial Resistance (2023–2027), emphasising surveillance, rational antibiotic use, and integration of community-level data [5]. The Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme also supports pharmacy-led AMS initiatives across Kenyan counties. However, little is known about how antibiotics are dispensed at the community level outside Nairobi, and whether dispensing patterns reflect the intended AMS goals. Understanding real-world dispensing practices is a necessary first step for designing contextually appropriate antimicrobial stewardship interventions in community pharmacy settings. This study therefore describes antibiotic dispensing practices in Kakamega County, western Kenya—an area representing rural and peri-urban pharmacy settings. We characterise the indications for antibiotic dispensing, patterns of over-the-counter (OTC) versus prescription dispensing, and factors associated with partial and repeat antibiotic courses, to inform local AMS policy and national surveillance priorities. Methods Study design and setting This was a cross-sectional study conducted across 22 community pharmacies in Kakamega County, western Kenya, between 3rd and 22nd August 2025. The county represents a mix of urban, peri-urban, and rural settings. Participating outlets were licensed under the Pharmacy and Poisons Board (PPB) and included both independent and chain pharmacies. All eligible dispensing events during the study period were included consecutively to minimise selection bias and capture real-world dispensing practices. A formal sample size calculation was not performed as the study aimed to include all available dispensing events within the defined time frame. Inclusion and exclusion criteria All consecutive dispensing events involving at least one systemic human antibiotic, irrespective of formulation or duration, during the study period were included. Dispensing of topical, veterinary, or non-systemic antimicrobial agents was excluded. Each entry represented a single antibiotic dispensing event. Data collection Pharmacy staff recorded antibiotic dispensing events using a structured data collection tool. Variables captured included dispensing source (over-the-counter [OTC] or prescription), clinical indication (as reported by the patient or assessed by the dispenser), antibiotic(s) dispensed, provider of indication (doctor, pharmacist or pharmacy technician, patient, or other), whether a full antibiotic course was supplied and reasons for partial courses, and self-reported antibiotic use within the previous month. Where no prescription was presented, the clinical indication reflected either patient self-report or assessment by pharmacy staff. No personally identifiable patient information was collected. Data management and cleaning Data were entered into Microsoft Excel and exported to Python (version 3.10) for cleaning and analysis. Free-text variables were standardised to ensure consistent spelling and grouping. Forty-seven age entries that were erroneously parsed as dates during data export were manually recoded to the appropriate 5–12 years age category prior to analysis. Clinical indications were grouped into eight categories: upper respiratory tract infection (URTI), lower respiratory tract infection (LRTI), skin or soft-tissue infection (SSTI), gastrointestinal infection (GI), urinary tract infection (UTI), dental infection, sexually transmitted infection (STI), and other or non-specific indications. Antibiotic names were standardised and grouped using individual drug names for commonly dispensed agents and clinically relevant antibiotic classes, informed by the World Health Organization’s AWaRe framework. Where more than one antibiotic was dispensed during a single encounter, each antibiotic was included separately in descriptive analyses of antibiotic use. Statistical analysis Descriptive statistics were used to summarise frequencies and percentages. Associations between categorical variables—including dispensing source, clinical indication, provider of indication, age group, partial course dispensing, and repeat antibiotic use—were evaluated using Pearson’s chi-square (χ²) test. Statistical significance was defined as p < 0.05. Analyses were performed using Python version 3.10 with the SciPy library (version 1.11.3). This study adheres to the STROBE guidelines for cross-sectional studies. This study was approved by the Masinde Muliro University of Science and Technology Institutional Scientific and Ethics Review Committee (REF: MMU/COR: 40312 Vol 6(01)) and the National Commission for Science, Technology and Innovation (NACOSTI) (License No: NACOSTI/P/25/4176035). All participating pharmacists and technicians provided verbal informed consent to join the study. No personally identifiable data were collected, and the ethics committees granted a waiver of individual patient consent due to the use of fully anonymised routine dispensing data. Additional information regarding the ethical, cultural, and scientific considerations specific to inclusivity in global research is included in the Supporting Information (S2 File). Results Dispensing source A total of 504 antibiotic dispensing events were recorded across 22 community pharmacies in Kakamega County. Of these, 224 (44.4%) involved over-the-counter (OTC) dispensing, 278 (55.2%) were prescription-based, and 2 (0.4%) dispensing events involved cases where a prescription was presented but additional antibiotics were requested and supplied without prescription. Clinical indications for antibiotic dispensing Using the predefined indication groupings, the most frequent indications for antibiotic dispensing were upper respiratory tract infections (URTI; n = 156, 31.0%), followed by lower respiratory tract infections (LRTI; n = 95, 18.8%), gastrointestinal infections (GI; n = 65, 12.9%), and skin or soft-tissue infections (SSTI; n = 55, 10.9%). Other indications included sexually transmitted infections (STI; n = 33, 6.5%), dental infections (n = 27, 5.4%), urinary tract infections (UTI; n = 20, 4.0%), sepsis (n = 11, 2.2%), and other or non-specific indications (n = 80, 16.5%) (Table 1). The distribution of clinical indications did not differ significantly by dispensing source (χ² = 18.47, df = 16, p = 0.297). 10.1371/journal.pone.0342353.t001Table 1Clinical indications for antibiotic dispensing by age group (n = 485).Indication<5 years5–12 years13–19 years20–64 years≥65 yearsTotal nUpper respiratory tract infection (URTI)191827848156Lower respiratory tract infection (LRTI)1071060895Gastrointestinal infection (GI)65743465Skin and soft-tissue infection (SSTI)84534455Sexually transmitted infection (STI)10624233Dental infection13219227Urinary tract infection (UTI)22311220Sepsis1017211Other/ non-specific indications1182729580Total n (%)59 (12.2)47 (9.7)88 (18.1)251 (51.8)40 (8.2)485 (100) Notes: Age data were available for 485 of 504 dispensing events; events with missing age data were excluded from age-stratified analyses. Forty-seven age entries originally parsed as dates were manually recoded to the correct 5–12 years category prior to analysis. Values are presented as frequencies (n) for each indication. Percentages are shown only for age group totals and are calculated based on the number of dispensing events with available age data (n = 485). Clinical indications for antibiotic dispensing by age group (n = 485). Notes: Age data were available for 485 of 504 dispensing events; events with missing age data were excluded from age-stratified analyses. Forty-seven age entries originally parsed as dates were manually recoded to the correct 5–12 years category prior to analysis. Values are presented as frequencies (n) for each indication. Percentages are shown only for age group totals and are calculated based on the number of dispensing events with available age data (n = 485). Provider of clinical indication Doctors were the most frequent source of antibiotic indications for dental infections, UTIs, and sepsis, while pharmacists or pharmacy technicians most commonly provided indications for LRTIs and SSTIs. Patients most frequently self-identified the need for antibiotics for URTIs and other non-specific indications. The association between indication category and source of indication was statistically significant (χ² = 54.84, df = 32, p = 0.007). The distribution of the source of clinical indication across infection categories is illustrated in Fig 1. Source of clinical indication for antibiotic dispensing by infection type. Stacked bar chart showing the proportion of antibiotic dispensing events by source of clinical indication (doctor, pharmacist or pharmacy technician, patient, or other) across major infection categories in community pharmacies in Kakamega County, western Kenya. Percentages are calculated within each infection category. Antibiotics dispensed Across all dispensing events, a total of 558 antibiotics were dispensed, reflecting that some encounters involved more than one antibiotic. Of the 504 dispensing events, 52 (10.3%) involved more than one antibiotic, with the majority involving two antibiotics and very few cases involving three or more. The most frequently dispensed antibiotics overall were amoxicillin (n = 92), cephalosporins (n = 85), azithromycin (n = 74), fluoroquinolones (n = 53), metronidazole (n = 52), and co-amoxiclav (n = 46). According to the WHO AWaRe classification, the majority of antibiotics dispensed belonged to the Access and Watch categories, with frequent use of Watch antibiotics such as macrolides and fluoroquinolones. Antibiotic selection by clinical indication Antibiotic choice varied by clinical indication (Table 2). Macrolides were the most frequently dispensed antibiotics for URTIs, closely followed by penicillins. For LRTIs, penicillins were the most commonly used antibiotics, followed by cephalosporins, with smaller contributions from macrolides and other antibiotic classes. Nitroimidazoles predominated in gastrointestinal infections, with substantial additional use of fluoroquinolones. Antibiotic use for SSTIs was heterogeneous, with a wide range of agents included within the “other” category, alongside use of nitroimidazoles and penicillins. Dental infections were most commonly treated with penicillins, often in combination with nitroimidazoles. Antibiotic selection for STIs and UTIs was heterogeneous, with contributions from cephalosporins, fluoroquinolones, tetracyclines, and other agents. 10.1371/journal.pone.0342353.t002Table 2Antibiotics dispensed by clinical indication.IndicationAntibiotic classnURTIMacrolides51Penicillins47Other42Cephalosporins18Nitroimidazoles3Fluoroquinolones1LRTIPenicillins50Cephalosporins24Other17Macrolides11Nitroimidazoles1Fluoroquinolones2GINitroimidazoles30Fluoroquinolones24Cephalosporins5Macrolides5Other5Penicillins2SSTIOther53Nitroimidazoles11Penicillins6Macrolides2Cephalosporins1UTIFluoroquinolones8Other8Penicillins3Cephalosporins3Macrolides2STICephalosporins25Other20Nitroimidazoles10Macrolides6DentalPenicillins21Other11Nitroimidazoles7SepsisOther9Cephalosporins3Nitroimidazoles2Macrolides1Other indicationsOther31Fluoroquinolones18Nitroimidazoles10Penicillins8Cephalosporins8Macrolides3 Notes: Counts represent the total number of times each antibiotic class was dispensed within each clinical indication category. Dispensing events involving more than one antibiotic are counted separately for each antibiotic. Antibiotics were grouped into classes based on pharmacological classification informed by the WHO AWaRe framework. Antibiotics dispensed by clinical indication. Notes: Counts represent the total number of times each antibiotic class was dispensed within each clinical indication category. Dispensing events involving more than one antibiotic are counted separately for each antibiotic. Antibiotics were grouped into classes based on pharmacological classification informed by the WHO AWaRe framework. Age distribution Age data were available for 485 of 504 (96.2%) dispensing events. Among these, 59 (12.2%) involved children aged <5 years, 47 (9.7%) aged 5–12 years, 88 (18.1%) aged 13–19 years, 251 (51.8%) aged 20–64 years, and 40 (8.2%) aged ≥65 years. The distribution of clinical indications by age group is presented in Table 1. Partial antibiotic courses Partial antibiotic courses were dispensed in 33 of 504 (6.5%) events. The most frequently reported reason was financial constraint (15/33, 45.5%), followed by patient preference for reduced quantities and stock shortages. There was no significant association between partial course dispensing and dispensing source (χ² = 1.94, df = 2, p = 0.38). Repeat antibiotic use Self-reported antibiotic use within the preceding month occurred in 156 of 504 (31.0%) dispensing events. Among these, 84 (53.8%) were repeats for the same condition, 49 (31.4%) for a different condition, and 23 (14.7%) were unspecified. Repeat use did not differ significantly by dispensing source (χ² = 0.83, df = 2, p = 0.66). Discussion This study provides one of the first detailed descriptions of antibiotic dispensing practices in community pharmacies outside Nairobi, Kenya. Across 22 outlets in Kakamega County, nearly half of all antibiotics were dispensed without a prescription, underscoring the continued accessibility of antibiotics through non-regulated channels. These findings are consistent with prior studies from sub-Saharan Africa reporting high levels of non-prescription antibiotic sales; however, the 44.4% OTC dispensing rate observed here exceeds estimates reported from urban Kenyan settings, suggesting more limited regulatory enforcement in peri-urban and rural areas [6–8]. The antibiotics dispensed were dominated by amoxicillin, azithromycin, and metronidazole, reflecting largely empiric antibiotic use in community settings where access to diagnostic testing is limited. Similar patterns have been reported across East Africa, where antibiotic choice is often driven by symptom-based assessment rather than microbiological confirmation [9]. According to the WHO AWaRe classification, a substantial proportion of antibiotics dispensed belonged to the Access and Watch categories. Of particular concern is the frequent use of macrolides and fluoroquinolones, which fall within the Watch category and are recommended for more restricted use due to their higher potential to drive antimicrobial resistance [5]. Detailed patterns of antibiotic class use across indications are presented in Table 2. Respiratory tract infections, including both URTIs and LRTIs, were the most common indications for antibiotic dispensing, accounting for nearly half of all events, consistent with prior research highlighting respiratory conditions as key drivers of antibiotic overuse in outpatient settings [10]. Antibiotic selection for URTIs was dominated by macrolides and penicillins, while LRTIs were most commonly treated with penicillins, followed by cephalosporins. This pattern suggests a combination of guideline-consistent prescribing alongside empiric escalation to broader-spectrum agents in some cases. In gastrointestinal infections, nitroimidazoles—particularly metronidazole—predominated, alongside substantial use of fluoroquinolones. While metronidazole use is consistent with treatment of certain parasitic and anaerobic infections, the concurrent use of fluoroquinolones may reflect empiric treatment approaches that do not always align with guideline-recommended therapy. Antibiotic use for skin and soft-tissue infections was heterogeneous, reflecting variability in prescribing practices and potential uncertainty in diagnosis or management at the community level. Dental infections were most commonly treated with penicillins, often in combination with nitroimidazoles, consistent with common clinical practice in settings where mixed infections are suspected. Pharmacists and pharmacy technicians played a central role in determining clinical indications for antibiotic use, particularly for LRTIs and SSTIs, while doctors most frequently provided indications for dental infections, UTIs, and sepsis. This pattern reflects the expanding clinical role of pharmacists in community settings, especially in contexts where access to formal medical care may be constrained. Similar findings have been reported in Ghana and Nigeria, where pharmacy staff frequently guide antibiotic selection in the absence of a prescription [11–13]. These results highlight an important opportunity to integrate community pharmacists more formally into county-level antimicrobial stewardship (AMS) programmes, including through targeted training, clinical decision support, and strengthened referral pathways. Incomplete antibiotic courses were dispensed in 6.5% of events, most commonly due to financial constraints, underscoring persistent socioeconomic barriers to full-course adherence. Although the proportion of partial courses was modest, even short interruptions or under-dosing may contribute to treatment failure and selection for resistance. These findings mirror reports from other low- and middle-income countries, where cost remains a major determinant of antibiotic adherence [14] Community AMS strategies must therefore balance efforts to restrict inappropriate use with measures to ensure affordable access to complete antibiotic courses. Repeat antibiotic use within the preceding month was reported in nearly one-third of dispensing events, often for the same condition. While repeat use was not significantly associated with dispensing source, such recurrent exposure increases the risk of antimicrobial resistance and may indicate unresolved infections, inadequate prior treatment, or inappropriate initial antibiotic selection. Strengthening patient counselling, improving continuity of care, and exploring mechanisms for shared dispensing records across pharmacies could help reduce unnecessary repeat antibiotic use. Overall, these findings reveal persistent gaps in antibiotic governance at the community level and underscore the central role of pharmacists in antibiotic selection and supply. Addressing inappropriate antibiotic use in settings such as Kakamega County will require strengthening regulatory enforcement alongside pragmatic, pharmacy-led stewardship interventions. Integrating community pharmacy dispensing data into Kenya’s AMR surveillance systems and National Action Plan on AMR (2023–2027) is essential to support locally responsive and sustainable AMS strategies. Conclusion Nearly half of antibiotics dispensed in community pharmacies in Kakamega County were supplied without a prescription, most commonly for respiratory tract infections. Amoxicillin, azithromycin, and metronidazole dominated antibiotic use, with substantial reliance on broad-spectrum agents across multiple indications. Incomplete antibiotic courses were frequently linked to financial constraints, and repeat antibiotic use was common. These findings highlight critical gaps in community antibiotic governance, including widespread non-prescription dispensing, reliance on broad-spectrum antibiotics, and barriers to completing treatment courses. The central role of pharmacists in determining antibiotic use further underscores the need for targeted antimicrobial stewardship interventions at the community level. Incorporating community pharmacy data into county-level surveillance and national AMR frameworks will be essential to optimise antibiotic use and mitigate the emergence of antimicrobial resistance. Supporting information Reasons for partial antibiotic course dispensing. Summary of reported reasons for dispensing incomplete antibiotic courses across community pharmacies in Kakamega County, Kenya. (DOCX) Inclusivity in Global Research Questionnaire. Completed PLOS ONE questionnaire on inclusivity and best practices in global research. (DOCX) 31 Mar 2026 -->PONE-D-26-02714-->-->Antibiotic dispensing practices and antimicrobial stewardship gaps in community pharmacies in Kakamega County, Kenya-->-->PLOS One Dear Dr. Turnbull-Jones, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Kindly address the comments from the two reviewers below Please submit your revised manuscript by May 15 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Eric Ogola, MPH Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 6. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: 1. Antimicrobial resistance (AMR) remains one of the leading global public health threats, 70 contributing to an estimated 4.95 million deaths in 2019, with the highest burden in sub- 71 Saharan Africa. Please re check for latest data if available as per WHO , or any other valid agencies 2. major thing which is highlighted in conclusion is highlight critical gaps in community antibiotic governance. kindly highlight other important aspects of this study. Reviewer #2: 1. The research and manuscript is well-structured. The manuscript can be accepted after minor revision since research like this may help to combat the menace of AMR in regions like Kenya. 2. The researchers mentioned in the methodology that they have followed STROBE guidelines for cross-sectional studies. But they have also described the study design as "prospective descriptive cross-sectional ".The design can be "cross-sectional study" since description of the methodology reveals that it is not prospective and since they have employed statistical tests also in interpreting data , the study is should be categorised as "analytical' rather than purely "descriptive". 3. For sampling, they have used consecutive prescription with antibiotic. But they have not provided a relevant justification for the sample "504" and the reason for choosing a particular sampling method. 4. Lines 154 - 155, they mentioned "both". How the dispensing source can be both OTC and prescription-based 5. Lines 178 - 179, they mentioned that few prescriptions had more than one antibiotic. But they did not mention how many prescriptions had two antibiotics, three antibiotics , etc. 6. In methodology and discussion they have included AwARe classification and it is missing in the results. To strengthen analysis, the authors should include the classification. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Dr. Saurabh Singh , Ex Professor, School of Pharmaceutical Sciences ,LPU Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 21 Apr 2026 Dear Editors, Thank you for the opportunity to revise and resubmit our manuscript entitled “Antibiotic dispensing practices and antimicrobial stewardship gaps in community pharmacies in Kakamega County, Kenya.” We are grateful to the editor and reviewers for their constructive and insightful comments, which have helped us to substantially strengthen the manuscript. We have carefully addressed all editorial and reviewer comments and provide a detailed, point-by-point response below. All changes have been incorporated into the revised manuscript. Editorial Comments 1. PLOS ONE formatting requirements We have revised the manuscript to fully comply with PLOS ONE formatting guidelines, including structure, section headings, and file naming conventions. The manuscript has been aligned with the PLOS ONE formatting templates provided. 2. Inclusivity in global research questionnaire A completed copy of the PLOS ONE inclusivity in global research questionnaire has been included as Supporting Information (S2 File), and this is referenced in the Methods section of the manuscript. 3. Ethics statement placement The ethics statement has been reviewed and is now included exclusively within the Methods section. It has been removed from any other sections to comply with journal requirements. 4. Funding information consistency The Funding statement has been reviewed and harmonised across all submission fields. All funding sources are now consistently reported in both the manuscript and submission system. The funding statement now reads, 'This work was supported by the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS), funded by the UK Department of Health and Social Care (DHSC) through the Fleming Fund [project reference: CwPAMS 2.5 A.01], and by Cambridge Global Health Partnerships (CGHP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'. 5. Supporting Information captions Captions for all Supporting Information files have been added at the end of the manuscript, and in-text citations have been updated to ensure consistency with PLOS ONE guidelines. 6. Data availability statement The Data Availability statement has been revised to clarify that the anonymised dataset will be made publicly available in Figshare without restriction upon publication. Data are provided as Supporting Information for peer review. 7. Reviewer-suggested citations We have reviewed all suggested citations and included relevant references where appropriate. No irrelevant or non-essential citations were added. 8. Reference list accuracy The reference list has been carefully reviewed and updated to ensure accuracy, completeness, and consistency with in-text citations. No retracted articles are cited. Reviewer #1 Comment 1: Update AMR mortality data We have updated the Background section to reflect the most comprehensive available estimates, including both direct (1.27 million) and associated (4.95 million) AMR-related deaths globally in 2019, based on the latest global analysis. Comment 2: Expand conclusions beyond governance gaps The Conclusion has been revised to incorporate additional key findings, including: • Substantial use of broad-spectrum antibiotics across multiple indications • Financial barriers to completing antibiotic courses • The central role of pharmacists in antibiotic selection This provides a more comprehensive summary of the study’s implications. Reviewer #2 Comment 1: General feedback We thank the reviewer for their positive assessment of the manuscript. Comment 2: Study design clarification The study design has been revised from “prospective descriptive cross-sectional” to “cross-sectional study”, consistent with STROBE guidelines and the analytical nature of the study. Comment 3: Sampling justification We have clarified that all eligible dispensing events during the study period were included consecutively to minimise selection bias. We have also stated that a formal sample size calculation was not performed due to the observational design and defined study period. Comment 4: Clarification of “both” dispensing source We have clarified that cases classified as “both” refer to instances where a prescription was presented but additional antibiotics were requested and supplied without prescription. Comment 5: Multiple antibiotics per prescription We have added detail to the Results section specifying that 52 (10.3%) dispensing events involved more than one antibiotic, most commonly involving two antibiotics, with very few involving three or more. Comment 6: Inclusion of AWaRe classification in results We have incorporated the WHO AWaRe classification into the Results section, noting that the majority of antibiotics dispensed belonged to the Access and Watch categories, with frequent use of Watch antibiotics such as macrolides and fluoroquinolones. This has also been further discussed in the Discussion section. Additional Revisions In addition to the points raised by reviewers and editors, we have undertaken further refinements to improve clarity and internal consistency: • Table 2 has been fully revised to ensure accurate, dataset-derived classification of antibiotics by clinical indication using consistent antibiotic class groupings. • The Results and Discussion sections have been updated to ensure complete alignment with the revised table and underlying dataset. • Minor language edits have been made throughout to improve clarity, precision, and readability. We believe these revisions have significantly strengthened the manuscript and addressed all concerns raised during the review process. We are grateful for the opportunity to revise our work and hope it is now suitable for publication in PLOS ONE. Thank you for your consideration. Yours sincerely, Eleanor Turnbull-Jones (on behalf of all authors) Submitted filename: Response to Reviewers.docx 30 Apr 2026 Antibiotic dispensing practices and antimicrobial stewardship gaps in community pharmacies in Kakamega County, Kenya PONE-D-26-02714R1 Dear Ms Eleanor Rachel Turnbull-Jones, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Sarah Nanzigu, Ph.D.,MSc.,MBchB Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: check all grammatical errors and editing mistakes in final manuscript, improve the quality of fig.1, recheck the citations once again Reviewer #2: review comments addressed. They did not include AWARE category in modifying result. But, they have mentioned about that briefly in discussion ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Dr. Saurabh Singh Reviewer #2: No ********** PONE-D-26-02714R1 PLOS One Dear Dr. Turnbull-Jones, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Sarah Nanzigu Academic Editor PLOS One